Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1314280 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:We have developed a composite infection vaccine technology (ciVAX) assembled from approved products for rapid response to pandemics and biothreat agents. ciVAX consists of an injectable biomaterial scaffold containing factors that recruit, reprogram and release dendritic cells (DC) in vivo. For bacterial infections, ciVAX contains Fc-Mannose-Binding Lectin (FcMBL) microbeads with captured PAMPs fractions from inactivated bacterial cell-wall lysates. ciVAX vaccination generates potent humoral and T cell responses to bacterial antigens, and ciVAX protects mice and pigs against lethal E coli challenge in sepsis and septic shock models
2021-01-22 | MSV000086751 | MassIVE
Project description:Pulmonary bacterial infections remain a major clinical challenge. Although vaccination reduces infection rates and mortality, the vulnerable post-vaccination immunity gap can still result in infection and vaccine failure. In addition, effective vaccines are unavailable for many clinically important bacterial pathogens. Here, we report a pulmonary mRNA-lipid nanoparticle (mRNA-LNP) vaccine incorporating a novel ionizable lipid engineered for localized high-level expression, which elicits both rapid and durable protections against bacterial lung infections, effectively bridging this critical window of vulnerability. Intratracheal delivery of mRNA-LNP rapidly primes lung neutrophils and macrophages into a transcriptionally pre-activated state, enhancing their phagocytic activity and enabling rapid, antigen-independent bacterial clearance during the early post-vaccination period (approximately 1-7 days). Subsequently, vaccination induces potent antigen-specific adaptive responses, conferring sustained protection against both laboratory and clinical drug-resistant Pseudomonas aeruginosa strains. Single-cell transcriptomics and immune profiling reveal coordinated activation of innate and adaptive immune programs. This dual-phase immune response exemplifies a paradigm-shifting vaccine design that integrates innate and adaptive immunity to confer both immediate and long-term protection. Our findings establish a mechanistic basis for rapid antibacterial defense and highlight pulmonary mRNA-LNP vaccination as a promising strategy for combating respiratory infections.
2026-06-17 | GSE335017 | GEO
Project description:Interventions: Dendritic cell-based cancer vaccination;Cancer, dendritic cell, vaccination
Primary outcome(s): Safety (adverse reactions, severe adverse events)
Study Design: single arm study,open(masking not used),uncontrolled control,single assignment
| 2613751 | ecrin-mdr-crc
Project description:Endosomal escape is a central barrier to efficient nucleic acid delivery by lipid nanoparticles (LNPs) and remains challenging to quantify in vivo. We report a library of branched ionizable phospholipids (BiPs) that markedly enhance mRNA delivery to the liver. The lead candidate BiP-20 outperformed the clinical benchmark LP01 by 4-fold for CRISPR–Cas9 editing of the TTR gene at low dose with rapid pharmacokinetics. To quantify the endosomal escape kinetics of BiP-20, we used LysoTag mice, which allow immunoisolation of liver lysosomes, and our Lysosomal Barcoding method, finding that ~9% of BiP-20 LNPs reach the cytosol within 30 minutes of administration. Lysosomal proteomics revealed mechanistic regulators of escape and BiP-20–induced alterations in endosomal maturation and recycling pathways. Loss of Rab7, a mediator of late endosomal maturation, increased LNP escape. These findings provide a potent class of ionizable lipids for RNA delivery, a method to quantify endosomal escape in vivo, and mechanistic insight into the endolysosomal determinants of LNP trafficking.
2026-01-20 | PXD072066 | Pride
Project description:The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) - engineered to express the WT1 protein - in patients with limited spread metastatic solid tumors, i.e. breast cancers, glioblastoma grade IV, sarcomas, malignant mesothelioma and colorectal tumors. Based on the results of our previously performed phase I study with autologous WT1 mRNA-transfected DC, the investigators hypothesize that the vaccination with DC will be well-tolerated and will result in an increase in WT1-specific CD8+ T cell responses.
| 2101939 | ecrin-mdr-crc
Project description:Mass spectrometry lipidomics dataset analyzing degradation pathways of ionizable lipids in mRNA lipid nanoparticles (LNPs) exposed to environmental stressors. UHPLC–TIMS-TOF MS was used to characterize lipid oxidation products and structural degradation of DLin-MC3-DMA (MC3), SM-102, and ALC-0315 under UV irradiation, oxidative conditions, thermal exposure, and freeze–thaw cycling.
2026-03-16 | PXD075449 | JPOST Repository
Project description:Lei et al. screen out Lactococcus lactis OMVs (Lac-OMVs) and develop metabolic-engineered NAD+-Lac-OMVs nanovaccine with potent tissue repair therapeutic effect. NAD+-Lac-OMVs sequentially activate dendritic cells by membrane component and reprogram inflammatory macrophages for anti-inflammation and bone repair by interior nicotinamide metabolites.
2026-03-23 | PXD076052 |